A Narrative Review of Novel Agents for Managing Heavily Treatment-Experienced People Living With HIV.
Objective: The objective of this review is to compare ibalizumab, fostemsavir, and lenacapavir, present the clinical trials evaluating each agent, and provide guidance on their use in highly-treatment experienced (HTE) population living with HIV (PWH). Data sources: A search of PubMed and clinicaltr...
| Publicado en: | Journal of Pharmacy Technology Vol. 40; no. 4; pp. 194 - 202 |
|---|---|
| Autores principales: | , , |
| Formato: | review tables/charts Journal Article |
| Publicado: |
Sage Publications Inc.
Aug2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=179022177&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 179022177 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 87551225 G2J jtl: Journal of Pharmacy Technology issn: 87551225 maglogo: Y pubinfo: dt: Aug2024 vid: 40 iid: 4 pid: 344 pub: Sage Publications Inc. place: Thousand Oaks, California artinfo: ui: 179022177 178672969 179022177 179022177 10.1177/87551225241259894 179022177 ppf: 194 ppct: 8 formats: tig: atl: A Narrative Review of Novel Agents for Managing Heavily Treatment-Experienced People Living With HIV. aug: au: Beran, Christina Duggan, Joan M. Sahloff, Eric G. affil: College of Pharmacy and Pharmaceutical Sciences, The University of Toledo, Toledo, OH, USA sug: subj: Antiretroviral Therapy, Highly Active HIV-Positive Persons Psychosocial Factors HIV Infections Drug Therapy Antibodies, Monoclonal Therapeutic Use Anti-HIV Agents Therapeutic Use Anti-Retroviral Agents Therapeutic Use Antibodies, Monoclonal Administration and Dosage Anti-HIV Agents Administration and Dosage Anti-Retroviral Agents Administration and Dosage Antibodies, Monoclonal Pharmacokinetics Anti-HIV Agents Pharmacokinetics Anti-Retroviral Agents Pharmacokinetics Drug Interactions Drug Resistance Virology Clinical Trials ab: Objective: The objective of this review is to compare ibalizumab, fostemsavir, and lenacapavir, present the clinical trials evaluating each agent, and provide guidance on their use in highly-treatment experienced (HTE) population living with HIV (PWH). Data sources: A search of PubMed and clinicaltrials.gov was conducted using the search terms: ibalizumab, fostemsavir, and lenacapavir. Study selection and data extraction: English-language, clinical publications were included. Data synthesis: Ibalizumab, fostemsavir, and lenacapavir, are each first-in-class agents, that have major differences in mechanism of action, route and frequency of administration, pharmacokinetic parameters, including elimination half-life, potential for drug-drug interactions, safety profiles, and cost. Each has been shown, when combined with an optimized background regimen (OBR) with at least one other active agent, to achieve virologic suppression in HTE-PWH. Conclusion: In HTE-patients, adding ibalizumab, fostemsavir, and/or lenacapavir to at least one other active agent can lead to virologic suppression in this difficult to treat population. Monotherapy with any of these agents is not recommended and will lead to a high likelihood of drug resistance. Selection of which agent(s) to include with an OBR will depend on other patient factors including concomitant medications, acceptance of formulations (oral vs. subcutaneous vs. intravenous infusion), and potential access (both insurance-based and transportation). Adherence to all agents in the regimen is paramount to successful outcomes. pubtype: Academic Journal doctype: review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|